NASDAQ$SIGA

SIGA Technologies, Inc · Q4 2021 earnings

Q4 2021 earnings · · Investor relations

Briefing

SIGA Technologies' financial performance significantly improved in Q4 2021, driven by increased product sales.

SIGA Technologies reported a substantial increase in revenue and net income for the fourth quarter of 2021, primarily due to increased product sales of oral TPOXX to the U.S. government. The company's strategic focus on health security and successful partnerships have contributed to its financial success.

  • Total revenues increased to $115.4 million in Q4 2021, compared to $37.8 million in Q4 2020.
  • Operating income rose to $94.0 million in Q4 2021, up from $26.8 million in Q4 2020.
  • Net income reached $73.2 million in Q4 2021, a significant increase from $20.1 million in Q4 2020.
  • Diluted income per share increased to $0.98 in Q4 2021, compared to $0.26 in Q4 2020.

Headline financials

Total Revenue

$115M

Previous: $37.7M+205.8%
EPS (adj)

$0.98

Previous: $0.26+276.9%
Net Income

$73.2M

Previous: $20.1M+264.2%
Operating Income

$94M

Previous: $26.8M+250.7%
Gross Profit

$97.9M

Previous: $30.4M+222.3%
Cash & Equivalents

$103M

Previous: $118M-12.5%
Total Assets

$215M

Previous: $150M+43.3%
Stock-Based Comp

$308K

Previous: $388K-20.4%

Revenue & EPS history

SIGA Technologies · Revenue · Quarterly

$115M

Q4 2021+205.8%vs Q4 2020
Beat estimate in 0 of 2 quarters(0%)
ActualEstimate

Revenue by segment

SIGA Technologies · $134M total across 2 segments · Q4 2021

  • Product Sales
    $127M+9.8%
  • R&D Revenues
    $6.87M-27.6%

Forward guidance

The press release contains forward-looking statements regarding SIGA's development programs, timelines for bringing products to market, and the impact of COVID-19 on SIGA's business. Actual results may differ due to various risks and uncertainties.

Tailwinds

  • Continued progress in development programs.
  • Potential for new products to reach the market.
  • Ongoing government contracts provide a stable revenue stream.
  • International expansion opportunities.
  • Potential for alternative uses or formulations of TPOXX.

Headwinds

  • Risk that BARDA may not exercise all contract options.
  • Risk of not completing contracts on schedule or according to terms.
  • Risk of contracts being modified or canceled by the U.S. government.
  • Uncertainty in the development of the international biodefense market.
  • Potential impact of the COVID-19 pandemic on operations and supply chain.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q4 2021

Historical avgQ4 2021

-0.2%

Avg return

Earnings day

+0.5%

Avg return

5 days after

+2.4%

Avg return

30 days after

41%

26 / 64 earnings

Positive

+31.9%

Q4 2023

Best reaction

-27.8%

Q1 2024

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+0.4%-5.5%-8.5%
Q4 2025-3.0%-3.4%-22.8%
Q3 2025-20.2%-24.0%-24.1%
Q1 2025+4.4%+9.0%+10.8%
Q4 2024+7.0%+0.5%+6.4%
Q3 2024-1.9%-8.5%-9.8%
Q2 2024-12.8%-14.3%-9.5%
Q1 2024-27.8%-28.2%-26.7%
Q4 2023+31.9%+49.9%+88.3%
Q3 2023-4.4%-2.2%+16.9%
Q2 2023-3.7%-10.0%-21.9%
Q1 2023+5.1%+1.8%-0.7%
Q4 2022-3.8%-7.8%-13.4%
Q3 2022+7.5%+9.8%+1.1%
Q2 2022+27.4%+24.6%-21.0%
Q1 2022+3.6%+4.0%+60.7%
Q4 2021+3.0%+6.6%+22.4%
Q3 2021-0.7%+0.0%+2.8%
Q2 2021-2.9%-4.0%+9.1%
Q1 2021-0.7%-8.4%-10.4%
Q4 2020+1.7%+9.3%+1.2%
Q3 2020+2.0%+3.4%-0.9%
Q2 2020+14.3%+5.5%-1.9%
Q1 2020-1.4%+1.4%+2.9%
Q4 2019+10.4%+0.4%+0.2%
Q3 2019-3.2%-1.8%-19.8%
Q2 2019+0.2%-1.7%+2.7%
Q1 2019+1.5%-1.3%-12.8%
Q4 2018-4.4%-1.6%-6.3%
Q3 2018+8.4%+5.7%+29.1%
Q2 2018+0.3%+7.7%+1.4%
Q1 2018-0.5%+2.4%-3.9%
Q4 2017-0.6%-7.0%-2.3%
Q3 2017+2.8%-1.1%+3.9%
Q2 2017-1.6%-1.6%-1.9%
Q1 2017-0.3%+0.6%-8.0%
Q4 2016-0.6%+0.0%-4.1%
Q3 2016-5.7%+3.8%+54.8%
Q2 2016+4.5%+4.1%+11.4%
Q1 2016+1.1%
Q4 2015+1.1%
Q3 2015+2.4%
Q2 2015-0.9%
Q1 2015+5.7%
Q4 2014-1.3%
Q3 2014-0.7%
Q2 2014-4.9%
Q1 2014-1.4%
Q4 2013-2.7%
Q3 2013-3.5%
Q2 2013-2.8%
Q1 2011-2.4%
Q4 2012-2.5%
Q3 2012+6.5%
Q2 2012+5.3%
Q1 2012+4.5%
Q4 2011-1.4%
Q4 2009-1.4%
Q3 2010-6.1%
Q3 2011-6.1%
Q2 2011-12.0%
Q2 2010-12.0%
Q4 2010-12.0%
Q1 2010-1.4%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro